D. T. Özyükseler

Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?

D. Tural, M. Gümüş, Özgecan Dülgar, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

Melike Özçelik, D. T. Özyükseler, M. Başak, 2020, Asia-Pacific journal of clinical oncology.

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

M. Gümüş, R. Arıkan, I. Dogan, 2022, Journal of chemotherapy.

Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

A. Dirican, A. Sümbül, A. Alkan, 2021, International Journal of Clinical Oncology.

Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?

Y. Bozkaya, I. Cil, O. Köstek, 2019, Supportive Care in Cancer.

Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

M. Ayhan, A. Doğan, N. Turan, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

A. Dirican, A. Sümbül, A. Alkan, 2020, European urology focus.